Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00232479 · ClinicalTrials.gov registry record · Phase 2

Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by University of Miami.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
1
Study location

NCT00232479: Completed Phase 2 study of Breast Cancer, sponsored by University of Miami.

NCT00232479 is a Phase 2 study of Breast Cancer that has completed, run by University of Miami. The registered enrollment target is 48 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00232479, a Phase 2 study of Breast Cancer, has completed, sponsored by University of Miami.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2. This study evaluates a neoadjuvant regimen containing carboplatin, taxotere and herceptin when used in a dose dense manner in patients with large breast cancers. The endpoint of pathologic complete response is used as a surrogate marker for survival.

Primary Outcome

pCR is defined as the absence of invasive tumor from the surgical specimen of breast and axilla which is obtained after the chemotherapy regimen has been delivered.

Conditions Studied

Interventions

  • DRUG trastuzumab, docetaxel and carboplatin in dose dense regimen

Study Locations (1)

Florida

  • Jackson Memorial Hospital - Miami

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2005-09
Est. Completion 2008-06
Phase Phase 2
University of Miami

721 total trials

What the finished NCT00232479 record still lists

NCT00232479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which trastuzumab, docetaxel and carboplatin in dose dense regimen is the first listed.

NCT00232479 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT00232479 about?

NCT00232479 is a clinical study titled "Dose Dense Carboplatin, Taxotere and Herceptin As Primary Systemic Therapy in Breast Cancer". Dose dense therapy has been shown to increase survival in the adjuvant setting of breast cancer. It is unknown if dose dense therapy will improve survival in tumors that express her-2. This study evaluates a neoadjuvant regimen containing carboplatin, taxotere and herceptin when used in a dose dense...

What is the current status of trial NCT00232479?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2005-09. Estimated completion is 2008-06.

What conditions does trial NCT00232479 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00232479?

The interventions under investigation include: trastuzumab, docetaxel and carboplatin in dose dense regimen (DRUG).

Who is sponsoring clinical trial NCT00232479?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00232479 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00232479's enrollment target sits among peer trials

48 821st of 1224 higher than 394 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00232479, the US trial registry maintained by the National Library of Medicine. NCT00232479 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.